Free Trial
NASDAQ:QDEL

QuidelOrtho Q2 2025 Earnings Report

QuidelOrtho logo
$27.39 +1.06 (+4.03%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$27.41 +0.02 (+0.07%)
As of 07/25/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QuidelOrtho EPS Results

Actual EPS
N/A
Consensus EPS
$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

QuidelOrtho Revenue Results

Actual Revenue
N/A
Expected Revenue
$612.36 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

QuidelOrtho Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

QuidelOrtho Earnings Headlines

Genesis 14:13-17 [HIDDEN MEANING?]
A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available.
See More QuidelOrtho Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like QuidelOrtho? Sign up for Earnings360's daily newsletter to receive timely earnings updates on QuidelOrtho and other key companies, straight to your email.

About QuidelOrtho

QuidelOrtho (NASDAQ:QDEL) provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

View QuidelOrtho Profile

More Earnings Resources from MarketBeat